The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma

Table 2

Serum cytokine (x ± s).

		Study group(n = 22)	Control group(n = 27)	t	value
TNF-β1	Before treatment	45.33 ± 5.17	45.48 ± 5.29	0.048	0.962
	After treatment	21.90 ± 3.62	31.77 ± 4.02	9.934	<0.001
VEGF	Before treatment	38.67 ± 4.95	37.99 ± 4.97	0.477	0.636
	After treatment	16.36 ± 2.77	22.73 ± 2.98	7.679	<0.001
TIMP-1	Before treatment	82.39 ± 8.51	83.02 ± 8.86	0.252	0.802
	After treatment	36.04 ± 5.82	47.11 ± 6.54	6.188	<0.001
MMP-2	Before treatment	185.36 ± 26.62	186.34 ± 27.03	0.127	0.899
	After treatment	57.67 ± 5.39	76.47 ± 7.98	9.427	<0.001

The value for the difference between the study group and the control group is <0.05.